Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter
NCT04264962 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 300
Last updated 2021-10-12
Summary
Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy in 1 year recurrence for patients belong to Hepatocellular Carcinoma less than 3 cm in diameter.
Conditions
Interventions
- DRUG
-
Yang Yin Fu Zheng Jie Du therapy
Yang Yin Fu Zheng Jie Du is a Chinese herbal compound.
- OTHER
-
Routine medical care
Routine medical care
Sponsors & Collaborators
-
Xiyuan Hospital of China Academy of Chinese Medical Sciences
collaborator OTHER -
Beijing Ditan Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2021-02-28
- Completion
- 2021-02-28
Countries
- China
Study Locations
More Related Trials
-
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
NCT05596630 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma
NCT06463522 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment
NCT06923176 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy
NCT02725996 ·Status: UNKNOWN ·Phase: PHASE2
-
A Dose Escalation Trial of Radiation Therapy (RT) for Hepatocellular Carcinoma (HCC)
NCT00960167 ·Status: UNKNOWN ·Phase: PHASE1
-
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
NCT05057104 ·Status: UNKNOWN
-
Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma
NCT01570166 ·Status: UNKNOWN ·Phase: NA
-
Capecitabine to Prevent Recurrence of Hepatocellular Carcinoma After Curative Resection
NCT00561522 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma
NCT02969096 ·Status: UNKNOWN ·Phase: PHASE2
-
Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
NCT01125020 ·Status: UNKNOWN ·Phase: NA
-
Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma
NCT06715072 ·Status: NOT_YET_RECRUITING
-
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
NCT06644430 ·Status: RECRUITING
-
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma
NCT01833286 ·Status: UNKNOWN ·Phase: PHASE3
-
RFA Versus SBRT for Recurrent Small HCC
NCT04047173 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Hepatectomy on HCC Recurrence
NCT06390228 ·Status: COMPLETED
-
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
NCT01850667 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study on Patients With Hepatocellular Carcinoma (HCC)
NCT04021056 ·Status: UNKNOWN
-
Fu Zheng Jie Du Hua Yu Principle For Treatment Of Severe HBV Related Hepatocellular Carcinoma (FZJDHYPFTOSHBVHCC)
NCT05152498 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway
NCT01917370 ·Status: UNKNOWN
-
Ablation Combined With PD-1 in HCC: Phase II Study
NCT04652440 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
NCT06265350 ·Status: RECRUITING ·Phase: NA
-
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
NCT06405321 ·Status: RECRUITING
-
Immunotherapy for Hepatocellular Carcinoma
NCT06241326 ·Status: RECRUITING
-
Targeted Internal Radiation Therapy in Advanced HCC Patients.
NCT02724267 ·Status: COMPLETED ·Phase: NA
-
The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
NCT03652467 ·Status: UNKNOWN ·Phase: PHASE1